Cytokinetics, Incorporated (CYTK)
Automate Your Wheel Strategy on CYTK
With Tiblio's Option Bot, you can configure your own wheel strategy including CYTK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CYTK
- Rev/Share 0.7269
- Book/Share -4.3433
- PB -15.6861
- Debt/Equity -1.9921
- CurrentRatio 6.8758
- ROIC -0.43
- MktCap 8105982790.0
- FreeCF/Share -3.7787
- PFCF -17.879
- PE -10.871
- Debt/Assets 0.7226
- DivYield 0
- ROE 2.3287
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | CYTK | Raymond James | -- | Market Perform | -- | -- | July 30, 2025 |
| Initiation | CYTK | Barclays | -- | Overweight | -- | $55 | April 24, 2025 |
| Initiation | CYTK | Citigroup | -- | Buy | -- | $86 | Feb. 7, 2025 |
| Initiation | CYTK | Stifel | -- | Buy | -- | $80 | Jan. 22, 2025 |
News
CYTK Deadline: CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit
Published: November 17, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Nov. 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (the "Class Period"), of the important November 17, 2025 lead plaintiff deadline. So what: If you purchased Cytokinetics common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
CYTK LAWSUIT ALERT: Levi & Korsinsky Notifies Cytokinetics, Incorporated Investors - Lead Plaintiff Deadline November 17, 2025
Published: November 17, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 17, 2025) - If you suffered a loss on your Cytokinetics, Incorporated (NASDAQ: CYTK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cytokinetics-incorporated-lawsuit-submission-form-2?prid=177791&wire=5&utm_campaign=7 or contact Joseph E. Levi, Esq.
Read More
Investors in Cytokinetics, Incorporated Should Contact Levi & Korsinsky Before November 17, 2025 to Discuss Your Rights – CYTK
Published: November 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsuit.
Read More
CYTK DEADLINE: ROSEN, GLOBAL INVESTOR RIGHTS COUNSEL, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important November 17 Deadline in Securities Class Action - CYTK
Published: November 17, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 17, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (the "Class Period"), of the important November 17, 2025 lead plaintiff deadline. SO WHAT: If you purchased Cytokinetics common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm
Published: November 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 17, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before November 17, 2025.
Read More
Portnoy Law Firm Announces Class Action on Behalf of Cytokinetics, Incorporated Investors
Published: November 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 17, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Cytokinetics, Incorporated, (“Cytokinetics” or the "Company") (NASDAQ: CYTK) investors of a class action on behalf of investors that bought securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). Cytokinetics investors have until November 17, 2025 to file a lead plaintiff motion.
Read More
Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: November 14, 2025 by: PRNewsWire
Sentiment: Neutral
BENSALEM, Pa. , Nov. 14, 2025 /PRNewswire/ -- The Law Offices of Howard G.
Read More
CYTK DEADLINE: Faruqi & Faruqi Reminds Cytokinetics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 17, 2025 - CYTK
Published: November 14, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Nov. 14, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cytokinetics, Incorporated ("Cytokinetics" or the "Company") …
Read More
Securities Lawsuit Alert: Cytokinetics, Incorporated (CYTK) Investors - Contact Levi & Korsinsky Before November 17, 2025
Published: November 13, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 13, 2025) - If you suffered a loss on your Cytokinetics, Incorporated (NASDAQ: CYTK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cytokinetics-incorporated-lawsuit-submission-form-2?prid=177266&wire=5&utm_campaign=2 or contact Joseph E. Levi, Esq.
Read More
Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth?
Published: November 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Cytokinetics' shares surge to a 52-week high as investor optimism grows over FDA approval prospects for aficamten.
Read More
CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm
Published: November 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before November 17, 2025.
Read More
Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: November 12, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Nov. 12, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) have opportunity to lead the securities fraud class action lawsuit.
Read More
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cytokinetics, Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: November 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK) and certain of its officers.
Read More
Class Action Filed Against Cytokinetics, Incorporated (CYTK) Seeking Recovery for Investors – Contact The Gross Law Firm
Published: November 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK).
Read More
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Cytokinetics (CYTK) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Published: November 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK). The lawsuit alleges Defendants represented that Cytokinetics expected approval from the U.S. Food and Drug Administration ("FDA") for its NDA for aficamten in the second half of 2025, based on a September 26, 2025 PDUFA date, and failed to disclose material risks related to the Company's failure to submit a Risk Evaluation and Mitigation Strategy ("REMS") that could delay the regulatory process.
Read More
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics
Published: November 07, 2025 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - November 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cytokinetics, Incorporated ("Cytokinetics" or …
Read More
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cytokinetics, Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: November 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK) and certain of its officers.
Read More
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Cytokinetics
Published: November 06, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)---- $CYTK #CYTK--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. On May 1, 2025, Cytokinetics, Inc. announ.
Read More
CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm
Published: November 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before November 17, 2025.
Read More
Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: November 04, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Nov. 4, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK). IF YOU SUFFERED A LOSS ON YOUR CYTOKINETICS INVESTMENTS, CLICK HERE BEFORE NOVEMBER 17, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
Read More
CYTK INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics
Published: November 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $10,000 In Cytokinetics To Contact Him Directly To Discuss Their Options
Read More
CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm
Published: November 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before November 17, 2025.
Read More
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics
Published: November 03, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Cytokinetics To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Nov. 3, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cytokinetics, Incorporated ("Cytokinetics" or …
Read More
ROSEN, A LEADING AND RANKED FIRM, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CYTK
Published: October 31, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (the “Class Period”), of the important November 17, 2025 lead plaintiff deadline.
Read More
CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm
Published: October 31, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 31, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before November 17, 2025.
Read More
Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: October 31, 2025 by: PRNewsWire
Sentiment: Neutral
BENSALEM, Pa. , Oct. 31, 2025 /PRNewswire/ -- The Law Offices of Howard G.
Read More
Cytokinetics, Incorporated Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before November 17, 2025 to Discuss Your Rights – CYTK
Published: October 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK).
Read More
Deadline Alert: Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: October 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 17, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”).
Read More
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cytokinetics, Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: October 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK) and certain of its officers.
Read More
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics
Published: October 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options
Read More
About Cytokinetics, Incorporated (CYTK)
- IPO Date 2004-04-30
- Website https://www.cytokinetics.com
- Industry Biotechnology
- CEO Robert I. Blum
- Employees 498